In order to further identify the key factors related to drug resistance of PD-1 mMAB in esophageal cancer, we performed Multi-label immunofluorescence assay validation on tissue sections of PD-1 mMAB sensitive and PD-1 mMAB resistant samples of ESCC patients after anti-PD-1 treatment. Here, PDCD1 is linked to esophageal cancer.